Stockscreener 앱 받기
22.35
5.78%
-1.37
시간 외 거래:
22.59
0.24
+1.07%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace
Open-Label Extension Data Confirms Sustained Benefit of - GlobeNewswire
BridgeBio's Acoramidis Shows 36% Mortality Reduction in ATTR-CM Trial Extension | BBIO Stock News - StockTitan
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL - The Bakersfield Californian
BridgeBio Pharma Announces Publication in the New England - GlobeNewswire
Shareholders in BridgeBio Pharma (NASDAQ:BBIO) have lost 44%, as stock drops 12% this past week - Simply Wall St
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Scotiabank Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst — A Buy, With Caveats (BBIO) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings - MarketBeat
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring - TipRanks
No-Moat BridgeBio's Valuation Driven by Pending Approval of Acoramidis; Positive Long-Term Outlook - Morningstar
BridgeBio Pharma Inc Reports Q3 2024 Revenue of $2.7 Million, Mi - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates - MSN
BridgeBio Pharma earnings beat by $0.13, revenue topped estimates - Investing.com UK
BridgeBio Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic - Barchart
Achondroplasia Market to Show Remarkable Growth Trends from - openPR
BridgeBio Pharma: Q3 Earnings Snapshot - San Antonio Express-News
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - The Manila Times
WCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Gene therapy shows promise in Canavan disease trial By Investing.com - Investing.com Australia
Citi reiterates Buy rating on BridgeBio shares, cites clinical results By Investing.com - Investing.com Canada
Gene therapy shows promise in Canavan disease trial - Investing.com
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene - The Bakersfield Californian
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Scotiabank Initiates Coverage of BridgeBio Pharma (BBIO) with Sector Outperform Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $46.00 by Analysts at Leerink Partners - MarketBeat
Equities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO) - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for BBIO Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at Scotiabank - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.7%Time to Buy? - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market Emerging - openPR
3.66%
1.11%
자본화:
|
볼륨(24시간):